BioCentury
ARTICLE | Company News

Abzena, Alpha Cancer deal

June 16, 2014 7:00 AM UTC

Abzena's PolyTherics Ltd. subsidiary partnered with Alpha Cancer to develop drug conjugates to treat cancer. PolyTherics will use its ThioBridge linker technology to attach an undisclosed cytotoxic drug to Alpha Cancer's recombinant human alpha fetoprotein (AFP) that targets AFP receptors. Alpha Cancer has exclusive, worldwide rights to recombinant human AFP from Merrimack Pharmaceuticals Inc. (NASDAQ:MACK, Cambridge, Mass.). PolyTherics and Alpha Cancer could not be reached for details. ...